ADC ADCC ADCP |
Antibody-drug conjugate Antibody-dependent cellular cytotoxicity Antibody-dependent cellular phagocytosis; |
AML | Acute myeloid leukemia |
APC-H7 | Allophycocyanine-Hilite®7 |
ASM | Aggressive systemic mastocytosis |
BM BMMC |
Bone marrow Bone marrow mast cell |
CAR | Chimeric antigen receptor |
CM | Cutaneous mastocytosis |
CR | Complete remission |
EMA | European Medicines Agency |
FDA | US Food and Drug Administration |
FITC | Fluorescein isothiocyanate |
ISM | Indolent systemic mastocytosis |
ISMMC | Indolent systemic mastocytosis with MC-restricted KIT mutation |
ISMML | Indolent systemic mastocytosis with multilineal KIT-mutated |
KIT | Stem cell factor receptor |
MC | Mast cell |
MCL | Mast cell leukemia |
MFI ORR |
Mean fluorescence intensity Overall response rate |
PacB | Pacific blue |
PacO | Pacific orange |
PE | Phycoerythrin |
PeCy7 | Phycoerythrin-cyanine 7 |
PerCPCy5.5 | Peridinin-chlorophyll protein-cyanine 5.5 |
PNA | Peptide nucleic acid |
REMA | Spanish Network on Mastocytosis |
SI | Stain index |
SM | Systemic mastocytosis |
SM-AHN | Systemic mastocytosis with an associated clonal non-MC lineage disease |
SSM | Smoldering systemic mastocytosis |
TKI | Tyrosine-kinase inhibitor |
WDSM | Well-differentiated systemic mastocytosis |
WHO | World Health Organization |